Better Know a Marijuana Stock: Arena Pharmaceuticals


Flickr / Jim Makos / (CC BY-ND 2.0)

Unlike GW Pharmaceuticals and Zynerba Pharmaceuticals, which rely on cannabinoid-based medicines to fill out the entirety of their drug-development pipelines, Arena Pharmaceuticals is one of the drug developers like Insys Therapeutics and Cara Therapeutics that have some of their pipelines devoted to cannabinoid-type therapeutics or CB agonists and other portions devoted to non-cannabinoid medicines.

Arena Pharmaceuticals’ pipeline currently consists of three clinical-stage therapies and a small handful of partnered programs.

View Original Article Here

Repost is the designation for articles collected from the Internet whose content may interest our readers. These articles are not written by our staff and they do not necessarily reflect our views.

Related posts